Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT00050752
View directory record Official record
Conditions
Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1,130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

NCT02026960
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Genitourinary Cancer (Bladder, Prostate or Testicular)
Interventions
RNA extraction and amplification from biopsy specimens
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Preventing Urinary Tract Infection Post-Surgery

NCT01346774
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cranberry powder capsules, Placebo powder capsules
Drug
Lead sponsor
Betsy Foxman
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785
View directory record Official record
Conditions
Bladder Cancer
Interventions
SCH 721015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

NCT00407160
View directory record Official record
Conditions
Kidney Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population

NCT03699696
View directory record Official record
Conditions
Acute Kidney Injury, Hypotension, Anesthesia; Adverse Effect
Interventions
Propofol
Drug
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

NCT03926117
View directory record Official record
Conditions
Chronic Kidney Diseases, Inflammation
Interventions
Ziltivekimab
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
49
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Recruiting No phase listed Observational

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Interventions
QUELIMMUNE (SCD-PED)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
Up to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

NCT03015623
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SBI-101, Sham
Biological · Device
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

NCT03795389
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
Interventions
DM199
Drug
Lead sponsor
DiaMedica Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Urodynamic Testing: Can we Improve Patient Experience?

NCT02742389
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive, Lower Urinary Tract Symptoms
Interventions
Preprocedure Telephone Call
Other
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 14, 2026, 1:19 PM EDT
Withdrawn Not applicable Interventional

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

NCT00167791
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

Quality of Life and Symptom Management in Patients With Bladder Cancer

NCT00772018
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
David Latini
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

NCT00043368
View directory record Official record
Conditions
Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
Interventions
PF-3512676
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
31
States / cities
Berkely, California • Gilroy, California • Hollister, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

NCT00971620
View directory record Official record
Conditions
Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

NCT00731315
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Computer-assisted treatment group, Usual care group
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis

NCT02457715
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer, Brain Cancer, ALS
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Edgewater, Florida • Orlando, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Validation of the Wisconsin Stone-QOL

NCT02188108
View directory record Official record
Conditions
Urolithiasis, Nephrolithiasis, Kidney Stones
Interventions
Wisconsin Stone-QOL survey
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Withdrawn Not applicable Interventional

Health Interventions in Men Undergoing Radical Prostatectomy

NCT01748110
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence
Interventions
Intensive Fitness Intervention, TRIMM
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
lenvatinib, everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Duarte, California • Whittier, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 1:19 PM EDT